PMID- 31064675
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20210109
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 37
IP  - 25
DP  - 2019 May 31
TI  - Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project.
PG  - 3296-3302
LID - S0264-410X(19)30568-7 [pii]
LID - 10.1016/j.vaccine.2019.04.080 [doi]
AB  - OBJECTIVES: We evaluate safety of routine vaccination among adults infected with 
      human immunodeficiency virus (HIV) in five healthcare organizations in the United 
      States. METHODS: We conducted a retrospective cohort study of HIV-infected adults 
      who received inactivated influenza vaccines, hepatitis B vaccines, pneumococcal 
      vaccines, or tetanus, diphtheria, and acellular pertussis vaccines between 2002 
      and 2013. We conducted self-controlled case series analysis to estimate the 
      relative risk (RR) for 11 pre-specified adverse events (AEs) requiring medical 
      attention. RESULTS: Among 20,417 HIV-infected adults (90.2% male), a total of 
      137,674 vaccine doses were administered. Based on ICD-9 codes, we detected an 
      increased risk of cellulitis and infection (RR: 1.18, 95% CI: 1.03-1.35) among 
      all patients, and an increased risk of stroke/cerebrovascular diseases among 
      patients with an HIV viral load >10,000 copies/ml (adjusted RR: 3.94, 95% CI: 
      1.32-11.72). Further analyses on chart confirmed cases of stroke/cerebrovascular 
      diseases indicated no statistically significant increased risk (adjusted RR: 
      1.72, 95% CI: 0.41-7.24). There was no evidence of increased risk for other AEs 
      following routine vaccination in HIV-infected adults. CONCLUSIONS: Routinely 
      administered vaccines are generally safe for HIV-infected adults.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Hechter, Rulin C
AU  - Hechter RC
AD  - Kaiser Permanente Southern California, USA. Electronic address: 
      Rulin.C.Hechter@kp.org.
FAU - Qian, Lei
AU  - Qian L
AD  - Kaiser Permanente Southern California, USA. Electronic address: 
      Lei.X.Qian@kp.org.
FAU - Tartof, Sara Y
AU  - Tartof SY
AD  - Kaiser Permanente Southern California, USA. Electronic address: 
      Sara.Y.Tartof@kp.org.
FAU - Sy, Lina S
AU  - Sy LS
AD  - Kaiser Permanente Southern California, USA. Electronic address: Lina.S.Sy@kp.org.
FAU - Klein, Nicola P
AU  - Klein NP
AD  - Kaiser Permanente Northern California, USA. Electronic address: 
      Nicola.Klein@kp.org.
FAU - Weintraub, Eric
AU  - Weintraub E
AD  - Immunization Safety Office, Centers for Disease Control and Prevention, USA. 
      Electronic address: eiw8@cdc.gov.
FAU - Mercado, Cheryl
AU  - Mercado C
AD  - Kaiser Permanente Southern California, USA. Electronic address: 
      Cheryl.M.Carlson@kp.org.
FAU - Naleway, Allison
AU  - Naleway A
AD  - Kaiser Permanente Northwest, USA. Electronic address: Allison.Naleway@kpchr.org.
FAU - McLean, Huong Q
AU  - McLean HQ
AD  - Marshfield Clinic Research Institute, USA. Electronic address: 
      mclean.huong@marshfieldresearch.org.
FAU - Jacobsen, Steven J
AU  - Jacobsen SJ
AD  - Kaiser Permanente Southern California, USA. Electronic address: 
      Steven.J.Jacobsen@kp.org.
LA  - eng
GR  - CC999999/ImCDC/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20190504
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Influenza Vaccines)
RN  - 0 (Vaccines)
RN  - 0 (Vaccines, Combined)
RN  - 0 (Vaccines, Inactivated)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cerebrovascular Disorders/etiology
MH  - Electronic Health Records
MH  - Female
MH  - HIV Infections/complications/*immunology
MH  - Humans
MH  - Immunization Schedule
MH  - Influenza Vaccines/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stroke/etiology
MH  - United States
MH  - Vaccination/*adverse effects/*statistics & numerical data
MH  - Vaccines/*adverse effects
MH  - Vaccines, Combined/adverse effects
MH  - Vaccines, Inactivated/administration & dosage/adverse effects
MH  - Viral Load
MH  - Young Adult
PMC - PMC6538462
MID - NIHMS1029007
OTO - NOTNLM
OT  - HIV
OT  - Vaccine Safety Datalink
OT  - Vaccine safety
COIS- Conflicts of interest disclosures Hechter has received research support from 
      Novartis and GSK for unrelated studies. Tartof has received research support from 
      GSK and Merck for unrelated studies. Sy has received research support from 
      Novartis, GlaxoSmithKline, Novavax, and Dynavax. Klein has received research 
      support from Merck, Pfizer, Sanofi Pasteur, Protein Science (now Sanofi Pasteur), 
      GSK, MedImmune, and Dynavax. Mercado and Jacobsen have received research support 
      from Dynavax. Naleway has received research support from Pfizer and Merck for 
      unrelated studies. Qian, McLean, and Weintraub report no conflict of interest.
EDAT- 2019/05/09 06:00
MHDA- 2020/09/29 06:00
PMCR- 2019/06/30
CRDT- 2019/05/09 06:00
PHST- 2019/01/16 00:00 [received]
PHST- 2019/04/22 00:00 [revised]
PHST- 2019/04/25 00:00 [accepted]
PHST- 2019/05/09 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2019/05/09 06:00 [entrez]
PHST- 2019/06/30 00:00 [pmc-release]
AID - S0264-410X(19)30568-7 [pii]
AID - 10.1016/j.vaccine.2019.04.080 [doi]
PST - ppublish
SO  - Vaccine. 2019 May 31;37(25):3296-3302. doi: 10.1016/j.vaccine.2019.04.080. Epub 
      2019 May 4.